ASTRESSIN
中文名称 | ASTRESSIN |
---|---|
中文同义词 | 收敛素;NLE-ASTRESSIN;NLE-ASTRESSIN拮抗剂多肽;ASTRESSIN TFA |
英文名称 | ASTRESSIN |
英文同义词 | H-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-cyclo(-Glu-Ala-His-Lys)-Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH2;M.W. 3563.24 C161H269N49O42;DPHE-HIS-LEU-LEU-ARG-GLU-VAL-LEU-GLU-NLE-ALA-ARG-ALA-GLU-GLN-LEU-ALA-GLN-GLU-ALA-HIS-LYS-ASN-ARG-LYS-LEU-NLE-GLU-ILE-ILE-NH2;D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Glu-Ala-His-Lys-Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH2 (LactaM bridge Glu30-Lys33);H-D-PHE-HIS-LEU-LEU-ARG-GLU-VAL-LEU-GLU-NLE-ALA-ARG-ALA-GLU-GLN-LEU-ALA-GLN-CYCLO(-GAMMA-GLU-ALA-HIS-EPSILON-LYS)-ASN-ARG-LYS-LEU-NLE-GLU-ILE-ILE-NH2;[D-PHE12, NLE21,38, GLU30, LYS33]-CORTICOTROPIN RELEASING FACTOR (12-41) (HUMAN, RAT);[D-PHE12,NLE21,38,GLU30,LYS33]-CORTICOTROPIN RELEASING FACTOR FRAGMENT 12-41;[D-PHE12, NLE21,38, GLU30, LYS33]-CRF (12-41), CYCLIC LACTAM, HUMAN, RAT |
CAS号 | 170809-51-5 |
分子式 | C161H269N49O42 |
分子量 | 3563.16 |
EINECS号 | 617-559-7 |
相关类别 | 多肽;标准品;目录多肽;CRF receptor and related |
Mol文件 | 170809-51-5.mol |
结构式 |
ASTRESSIN 性质
密度 | 1.43±0.1 g/cm3(Predicted) |
---|---|
储存条件 | −20°C |
形态 | 粉末 |
水溶解性 | Soluble to 1 mg/ml in 10% Acetic acid / water |
序列 | H-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Glu-Ala-His-Lys-Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH2 |
Astressin has low affinity for the CRF binding protein and high affinity (K i =2 nM) for the cloned pituitary receptor. Astressin shows high affinity for cloned human CRF-RA1 stably expressed in CHO cells and high potency to inhibit ACTH secretion.
Astressin is significantly more potent than any previously tested antagonist in reducing hypophyseal corticotropin (ACTH) secretion in stressed or adrenalectomized rats. Low doses of astressin (30 μg and 100 μg per kg) administered i.v. still produce a significant decrease in ACTH levels at 45 and 90 min, respectively. Astressin significantly reverses the anxiogenic-like response induced by both social stress and ICV rat/humanCRF (r/hCRF) on the elevated plus-maze, but fails to block the effects of r/hCRF-induced locomotor activity in a familiar environment. Intracerebroventricular infusion of the peptide both 30 min before and 10 min after seizures decreases damage in some hippocampal cell fields by as much as 84%, a magnitude of protection greater than reported for other CRF antagonists against other models of necrotic neuronal injury. Astressin protects even if administered only 10 min following excitotoxin exposure.
纯度(HPLC) ≥98.0%
醋酸根含量≤12.0%
水分含量≤8.0%
肽含量≥80.0%
内毒素≤50EU/mg
氨基酸组成分析≤±10%
安全信息
WGK Germany | 3 |
---|
提供商 | 语言 |
---|---|
英文
|
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/04/30 | HY-P0257 | ASTRESSIN Astressin | 170809-51-5 | 1mg | 1080元 |
2024/04/30 | HY-P0257 | ASTRESSIN Astressin | 170809-51-5 | 5mg | 2704元 |